Bintrafusp alfa
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uterine Cervical Neoplasms
Conditions
Uterine Cervical Neoplasms
Trial Timeline
Mar 30, 2020 → Dec 14, 2022
NCT ID
NCT04246489About Bintrafusp alfa
Bintrafusp alfa is a phase 2 stage product being developed by Merck for Uterine Cervical Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT04246489. Target conditions include Uterine Cervical Neoplasms.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05061823 | Phase 3 | Completed |
| NCT04727541 | Phase 2 | Terminated |
| NCT04428047 | Phase 2 | Terminated |
| NCT04349280 | Phase 1 | Terminated |
| NCT04489940 | Phase 2 | Terminated |
| NCT04246489 | Phase 2 | Completed |
| NCT04396886 | Phase 2 | Completed |
Competing Products
20 competing products in Uterine Cervical Neoplasms